BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21421857)

  • 21. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter.
    McCluskey AG; Mairs RJ; Tesson M; Pimlott SL; Babich JW; Gaze MN; Champion S; Boyd M
    J Nucl Med; 2012 Jul; 53(7):1146-54. PubMed ID: 22689924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [
    Kobayashi M; Mizutani A; Nishi K; Muranaka Y; Nishii R; Shikano N; Nakanishi T; Tamai I; Kleinerman ES; Kawai K
    Nucl Med Biol; 2020; 90-91():49-54. PubMed ID: 33032192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma.
    Altmann A; Kissel M; Zitzmann S; Kübler W; Mahmut M; Peschke P; Haberkorn U
    J Nucl Med; 2003 Jun; 44(6):973-80. PubMed ID: 12791828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
    Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of cisplatin and doxorubicin on 125I-meta-iodobenzylguanidine uptake in human neuroblastoma cell lines.
    Meco D; Lasorella A; Riccardi A; Servidei T; Mastrangelo R; Riccardi R
    Eur J Cancer; 1999 Aug; 35(8):1227-34. PubMed ID: 10615234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.
    Mairs RJ; Ross SC; McCluskey AG; Boyd M
    J Nucl Med; 2007 Sep; 48(9):1519-26. PubMed ID: 17704246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced 125I-meta-iodobenzylguanidine uptake and norepinephrine transporter density in the hearts of mice with MPTP-induced parkinsonism.
    Fukumitsu N; Suzuki M; Fukuda T; Kiyono Y; Kajiyama S; Saji H
    Nucl Med Biol; 2006 Jan; 33(1):37-42. PubMed ID: 16459257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
    Vaidyanathan G; Friedman HS; Keir ST; Zalutsky MR
    Br J Cancer; 1996 May; 73(10):1171-7. PubMed ID: 8630274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics.
    Zheng X; Naiditch J; Czurylo M; Jie C; Lautz T; Clark S; Jafari N; Qiu Y; Chu F; Madonna MB
    Cell Death Dis; 2013 Jul; 4(7):e740. PubMed ID: 23887631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging hNET reporter gene expression with 124I-MIBG.
    Moroz MA; Serganova I; Zanzonico P; Ageyeva L; Beresten T; Dyomina E; Burnazi E; Finn RD; Doubrovin M; Blasberg RG
    J Nucl Med; 2007 May; 48(5):827-36. PubMed ID: 17475971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma.
    Tang XX; Robinson ME; Riceberg JS; Kim DY; Kung B; Titus TB; Hayashi S; Flake AW; Carpentieri D; Ikegaki N
    Clin Cancer Res; 2004 Sep; 10(17):5837-44. PubMed ID: 15355914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local delivery of (131)I-MIBG to treat peritoneal neuroblastoma.
    Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
    Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1246-50. PubMed ID: 12811531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines.
    Hagiwara K; Tokunaga T; Iida H; Nagai H
    Anticancer Res; 2019 Jul; 39(7):3579-3584. PubMed ID: 31262882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
    McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
    Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells.
    Anton M; Wagner B; Haubner R; Bodenstein C; Essien BE; Bönisch H; Schwaiger M; Gansbacher B; Weber WA
    J Gene Med; 2004 Jan; 6(1):119-26. PubMed ID: 14716684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Plasma Membrane Monoamine Transporter is Highly Expressed in Neuroblastoma and Functions as an mIBG Transporter.
    Vieira LS; Zhang Y; López Quiñones AJ; Hu T; Singh DK; Stevens J; Prasad B; Park JR; Wang J
    J Pharmacol Exp Ther; 2023 Dec; 387(3):239-248. PubMed ID: 37541765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to
    Batra V; Gikandi A; Pawel B; Martinez D; Granger MM; Marachelian A; Park JR; Maris JM; Vo KT; Matthay KK; DuBois SG
    Pediatr Blood Cancer; 2024 Jan; 71(1):e30743. PubMed ID: 37885116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.
    Carlin S; Mairs RJ; McCluskey AG; Tweddle DA; Sprigg A; Estlin C; Board J; George RE; Ellershaw C; Pearson AD; Lunec J; Montaldo PG; Ponzoni M; van Eck-Smit BL; Hoefnagel CA; van den Brug MD; Tytgat GA; Caron HN
    Clin Cancer Res; 2003 Aug; 9(9):3338-44. PubMed ID: 12960120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
    Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.